ProCE Banner Activity

Young-PEARL Phase II Study of Palbociclib, Exemestane, and Leuprolide vs Capecitabine in Premenopausal Women With HR+/HER2- MBC

Slideset Download
Conference Coverage
Palbociclib in combination with endocrine therapy and OFS prolonged PFS vs single-agent capecitabine in premenopausal women with HR+/HER2- MBC.

Released: June 07, 2019

Expiration: June 05, 2020

No longer available for credit.

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro